Bayon is Now Part of EyeGate Pharmaceuticals!

Optopharmacologic Restoration of Light Perception

Bayon Therapeutics is an ophthalmic specialty pharmaceutical company focused on using specifically designed small molecules to restore the eyes’ ability to perceive and interpret vision in visually-impaired patients. 

About Us

Because vision matters

Bayon was founded in 2020 with the focus on developing a novel platform of small molecules for visually-impaired patients with high unmet needs. Our lead program is entering Clinical Trials, initially focused on patients in later stages of disease progression due to Retinitis Pigmentosa (all sub-forms). After demonstrating safety and efficacy, we plan to further develop our platform for use in patients with Geographic Atrophy, the later stages of Age-Related Macular Degeneration (dry AMD).

Leadership Team

Brian M Strem, PhD

EXECUTIVE DIRECTOR

Eric J Daniels, MD, MBA

EXECUTIVE DIRECTOR

Advisors & Collaborators

Rich Kramer, PhD

Professor of Neurobiology
Dept of Molecular & Cell Biology
University of California, Berkeley

Russell Van Gelder, MD, PhD

Professor & Chair
Dept of Ophthalmology
University of Washington

Erica Fletcher, PhD

Professor
Dept of Anatomy & Neuroscience
University of Melbourne

Quinton Oswald

Previous CEO & Commercial Roles
SARcode, Neurotech, Notal Vision, BMS, Novartis & Genentech

Robert Casson, MD, PhD

Head of Ophthalmology
Royal Adelaide Hospital

Big Idea, Small Molecules!

Research & Development

At Bayon, we are focused on studying a novel class of small molecules, often referred to as “Molecular Photoswitches”. These molecules have the ability to rapidly and reversibly change shape based on the presence or absence of light, also known as photoswitching. This photoswitching ability gives the molecule the ability to interact and stimulate key cells in the optical highway.

Our lead candidate, a small molecule known as “BENAQ”, specifically enters key downstream retinal cells (those no longer connected to viable rods and cones) and turns them into light sensing cells, capable of signaling the brain as to the presence or absence of light. The ability to detect the presence or absence of light is the foundation of vision, and unfortunately is lost in a number of key degenerative diseases of the eye.

Why a Small Molecule?
Small molecules, in contrast to gene therapies and other biological based therapeutics, are the most common type of drugs approved throughout the world. For Bayon, this translates to a shorter development timeline when compared to these more complex approaches (e.g. gene therapy).

When Can Patients Expect a Clinical Trial?
The company’s first clinical trial is planned for 2021 and will be recruiting patients throughout Australia who suffer from mid and late-stage Retinitis Pigmentosa. Our goal is to complete enrollment of this Phase 1b clinical study by the end of 2021. Please periodically check back to our website to obtain updates.

Targeting all forms of Retinitis Pigmentosa

More than 150 specific gene mutations cause retinitis pigmentosa, we can address them all.

Small Molecule Therapeutic

Simple intravitreal delivery with immediate onset of action.

Entering Clinical Trials

Phase 1b clinical trial for patients with mid and late-stage retinitis pigmentosa being planned. 

Contact Us

For more information, please contact us directly at [email protected]